Samir K Gupta1, Ziyue Liu2, Emily C Sims1, Matthew J Repass1, Laura S Haneline3, Mervin C Yoder3. 1. Department of Medicine, Indiana University School of Medicine, Indianapolis. 2. Department of Biostatistics, Indiana University School of Medicine, Indianapolis. 3. Department of Pediatrics, Indiana University School of Medicine, Indianapolis.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) may be related to cardiovascular disease through monocyte activation-associated endothelial dysfunction. METHODS: Blood samples from 15 HIV-negative participants (the uninfected group), 8 HIV-positive participants who were not receiving antiretroviral therapy (ART) (the infected, untreated group), and 15 HIV-positive participants who were receiving ART (the infected, treated group) underwent flow cytometry of endothelial colony-forming cells (ECFCs) and monocyte proportions. IncuCyte live cell imaging of 8 capillary proliferative capacity parameters were obtained from cord blood ECFCs treated with participant plasma. RESULTS: The ECFC percentage determined by flow cytometry was not different between the study groups; however, values of the majority of capillary proliferative capacity parameters (ie, cell area, network length, network branch points, number of networks, and average tube width uniformity) were significantly lower in infected, untreated participants as compared to values for uninfected participants or infected, treated participants (P < .00625 for all comparisons). CD14+CD16+ intermediate monocytes and soluble CD163 were significantly and negatively correlated with several plasma-treated, cord blood ECFC proliferative capacity parameters in the combined HIV-positive groups but not in the uninfected group. CONCLUSIONS: Cord blood ECFC proliferative capacity was significantly impaired by plasma from infected, untreated patients, compared with plasma from uninfected participants and from infected, treated participants. Several ECFC functional parameters were adversely associated with monocyte activation in the HIV-positive groups, thereby suggesting a mechanism by which HIV-related inflammation may impair vascular reparative potential and consequently increase the risk of cardiovascular disease during HIV infection.
BACKGROUND:Human immunodeficiency virus (HIV) may be related to cardiovascular disease through monocyte activation-associated endothelial dysfunction. METHODS: Blood samples from 15 HIV-negative participants (the uninfected group), 8 HIV-positive participants who were not receiving antiretroviral therapy (ART) (the infected, untreated group), and 15 HIV-positive participants who were receiving ART (the infected, treated group) underwent flow cytometry of endothelial colony-forming cells (ECFCs) and monocyte proportions. IncuCyte live cell imaging of 8 capillary proliferative capacity parameters were obtained from cord blood ECFCs treated with participant plasma. RESULTS: The ECFC percentage determined by flow cytometry was not different between the study groups; however, values of the majority of capillary proliferative capacity parameters (ie, cell area, network length, network branch points, number of networks, and average tube width uniformity) were significantly lower in infected, untreated participants as compared to values for uninfected participants or infected, treated participants (P < .00625 for all comparisons). CD14+CD16+ intermediate monocytes and soluble CD163 were significantly and negatively correlated with several plasma-treated, cord blood ECFC proliferative capacity parameters in the combined HIV-positive groups but not in the uninfected group. CONCLUSIONS: Cord blood ECFC proliferative capacity was significantly impaired by plasma from infected, untreated patients, compared with plasma from uninfected participants and from infected, treated participants. Several ECFC functional parameters were adversely associated with monocyte activation in the HIV-positive groups, thereby suggesting a mechanism by which HIV-related inflammation may impair vascular reparative potential and consequently increase the risk of cardiovascular disease during HIV infection.
Authors: Jonathan M Hill; Gloria Zalos; Julian P J Halcox; William H Schenke; Myron A Waclawiw; Arshed A Quyyumi; Toren Finkel Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: T Asahara; T Murohara; A Sullivan; M Silver; R van der Zee; T Li; B Witzenbichler; G Schatteman; J M Isner Journal: Science Date: 1997-02-14 Impact factor: 47.728
Authors: Julie A Mund; Harlan Shannon; Anthony L Sinn; Shanbao Cai; Haiyan Wang; Kamnesh R Pradhan; Karen E Pollok; Jamie Case Journal: Angiogenesis Date: 2013-07-23 Impact factor: 9.596
Authors: Jun Hee Lee; Sang Hun Lee; So Young Yoo; Takayuki Asahara; Sang Mo Kwon Journal: Arterioscler Thromb Vasc Biol Date: 2013-05-02 Impact factor: 8.311
Authors: Jason V Baker; Katherine Huppler Hullsiek; Amrit Singh; Eleanor Wilson; Keith Henry; Ken Lichtenstein; Nur Onen; Erna Kojic; Pragna Patel; John T Brooks; Howard N Hodis; Matt Budoff; Irini Sereti Journal: AIDS Date: 2014-03-27 Impact factor: 4.177
Authors: Samir K Gupta; Changyu Shen; Sharon M Moe; Lisa M Kamendulis; Mitchell Goldman; Michael P Dubé Journal: PLoS One Date: 2012-09-20 Impact factor: 3.240
Authors: Sarvesh Chelvanambi; Samir K Gupta; Xingjuan Chen; Bradley W Ellis; Bernhard F Maier; Tyler M Colbert; Jithin Kuriakose; Pinar Zorlutuna; Paul Jolicoeur; Alexander G Obukhov; Matthias Clauss Journal: Circ Res Date: 2019-08-27 Impact factor: 17.367